Toxicities | P67.5 | P70 | P* | ||||
---|---|---|---|---|---|---|---|
Grade 0 | Grade 1-2 | Grade 3-4 | Grade 0 | Grade 1-2 | Grade 3-4 | ||
Acute toxicities | Â | Â | Â | Â | Â | Â | Â |
 Skin reaction | 5 (3.4%) | 137 (92.5%) | 6 (4.1%) | 5 (3.4%) | 136 (91.9%) | 7 (4.7%) | 0.961 |
 Mucositis | 2 (1.4%) | 133 (89.8%) | 13 (8.8%) | 1 (0.7%) | 141 (95.2%) | 6 (4.1%) | 0.207 |
 Xerostomia | 2 (1.4%) | 146 (98.6%) | 0 | 7 (4.7%) | 141 (95.3%) | 0 | 0.091 |
 Pharyngo-esophagitis | 0 | 144 (97.3%) | 4 (2.7%) | 4 (2.7%) | 143 (96.6%) | 1 (0.7%) | 0.055 |
 Leucopenia | 31 (20.9%) | 79 (53.4%) | 38 (25.7%) | 58 (39.2%) | 80 (54.0%) | 10 (6.8%) | 0.000 |
 Anemia | 73 (49.3%) | 71 (48.0%) | 4 (2.7%) | 137 (92.6%) | 11 (7.4%) | 0 | 0.000 |
 Thrombocytopenia | 118 (79.7%) | 23 (15.6%) | 7 (4.7%) | 140 (94.6%) | 8 (5.4%) | 0 | 0.000 |
 Weight loss | <5% 13 (8.8%) | 5%-10% 39 (26.3%) | ≥10% 96 (64.9%) | <5% 16 (10.8%) | 5%-10% 47 (31.7%) | ≥10% 85 (57.5%) | 0.423 |
Late toxicities | Grade 0 | Grade 1 | Grade 2+ | Grade 0 | Grade 1 | Grade 2+ | Â |
 Subcutaneous fibrosis | 92 (62.2%) | 53 (35.8%) | 3 (2.0%) | 87 (58.8%) | 51 (34.5%) | 10 (6.7%) | 0.139 |
 Xerostomia | 29 (19.6%) | 111 (75.0%) | 8 (5.4%) | 19 (12.8%) | 122 (82.4%) | 7 (4.7%) | 0.263 |
 Otitis media | 116 (78.4%) | 32 (21.6%) | 0 | 116 (78.4%) | 31 (20.9%) | 1 (0.7%) | 0.602 |
 Taste changes | 106 (71.6%) | 41 (27.7%) | 1 (0.7%) | 120 (81.1%) | 25 (16.9%) | 3 (2.0%) | 0.057 |
 Dehisce difficulty | 122 (82.4%) | 25 (16.9%) | 1 (0.7%) | 132 (89.2%) | 16 (10.8%) | 1 (0.7%) | 0.306 |
 Hearing loss | 75 (50.7%) | 60 (40.5%) | 13 (8.8%) | 80 (54.1%) | 59 (39.9%) | 9 (6.1%) | 0.639 |
 Tooth and periodontal diseases | 86 (58.1%) | 56 (37.8%) | 6 (4.1%) | 80 (54.1%) | 52 (35.1%) | 16 (10.8%) | 0.086 |
 Hypothyroidism | 143 (96.6%) | 4 (2.7%) | 1 (0.7%) | 138 (93.2%) | 8 (5.4%) | 2 (1.4%) | 0.416 |